Annals of Oncology 14:630-637, 2003
© 2003 European Society for Medical Oncology
Original Paper |
Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours
1 Centre René Gauducheau, Nantes-Saint-Herblain; 2 Institut Gustave Roussy, Villejuif; 3 Institut de Recherche Pierre Fabre, Boulogne-Billancourt, France
Received 28 October 2002; revised 18 November 2002; accepted 3 December 2002
Background:
Vinflunine is a novel vinca alkaloid obtained by semi-synthesis using super-acidic chemistry to selectively introduce two fluorine atoms at the 20' position of vinorelbine. In human tumour xenografts, vinflunine showed definite antitumour activity in seven out of 11 tumours tested compared with three out of 11 for vinorelbine.
Patients and methods:
In this phase I study, vinflunine was administered to 31 patients with advanced malignancies as a 10-min i.v. infusion every 3 weeks according to an escalating schedule of doses between 30 and 400 mg/m2.
Results:
Pharmacokinetic parameters and toxicities were assessed and, at 400 mg/m2, three out of five patients experienced dose-limiting toxicity. At the maximum tolerated dose (MTD), i.e. 400 mg/m2, the toxicity profile of vinflunine consisted mainly of mucositis, constipation and neutropenia of short duration. Vinflunine area under the curve increased as a proportion of the administered dose whereas no saturation of elimination was observed.
Conclusion:
The MTD of vinflunine was achieved at 400 mg/m2 every 3 weeks. According to protocol rules, the recommended dose was established at 350 mg/m2. A preliminary assessment of first patients included in early phase II trials led to reduction of the recommended dose to 320 mg/m2 every 3 weeks for further development of vinflunine. Three partial responses (two in breast carcinoma, one in renal cell carcinoma) suggest that activity is likely to be seen in less heavily pretreated patient populations.
Key words: dose-proportionality, pharmacokinetics, phase I study, safety, vinflunine
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Bennouna, J.-P. Delord, M. Campone, and L. Nguyen Vinflunine: A New Microtubule Inhibitor Agent Clin. Cancer Res., March 15, 2008; 14(6): 1625 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Talbot, J. Margery, G. Dabouis, G. Dark, H. Taylor, H. Boussemart, V. Cadic, M.-C. Pinel, A. Riviere, L. Ollivier, et al. Phase II Study of Vinflunine in Malignant Pleural Mesothelioma J. Clin. Oncol., October 20, 2007; 25(30): 4751 - 4756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Pourroy, M. Carre, S. Honore, V. Bourgarel-Rey, A. Kruczynski, C. Briand, and D. Braguer Low Concentrations of Vinflunine Induce Apoptosis in Human SK-N-SH Neuroblastoma Cells through a Postmitotic G1 Arrest and a Mitochondrial Pathway Mol. Pharmacol., September 1, 2004; 66(3): 580 - 591. [Abstract] [Full Text] [PDF]
|
|